Merck’s $11.5bn Acceleron Buy Partially Fills Future Keytruda Revenue Gap
Deal Expands Existing Cardiovascular Portfolio
Executive Summary
The company announced the biggest biopharma M&A deal of the year so far, but Merck will need more large deals to manage declining sales when its top-selling product faces biosimilars in 2028.
You may also be interested in...
BMS’s Phase III Reblozyl Trial Hits Mark In First-Line, Lower-Risk Myelodysplastic Syndrome
The drug’s success in the Phase III COMMANDS trial could double its addressable market, though some analysts said durability remains a question.
Merck Revenue Soars, Setting High Bar For Future Growth
With pharma sales up 13% in Q3, questions mount about investments in its pipeline to diversify beyond Keytruda and keep the momentum going after its top seller faces biosimilars in 2028.
Merck’s Sotatercept Hits Phase III Marks In Mid-Stage PAH Patients
The pharma’s pulmonary arterial hypertension candidate, touted as a future blockbuster seller, showed benefit on six-minute walk distance and several secondary endpoints in Phase III STELLAR.